Last reviewed · How we verify
NCT05851911
Passive Transmission of COVID-19 Antibody From Mother to Infant
trial testing sars-cov-2 vaccine or infection in Passive Transmission of Maternal and Infant Antibodies in 300 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Children's Hospital of Chongqing Medical University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 September 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 December 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- sars-cov-2 vaccine or infection — full drug profile →
Conditions studied
- Passive Transmission of Maternal and Infant Antibodies — all drugs for Passive Transmission of Maternal and Infant Antibodies →
Sponsor
Children's Hospital of Chongqing Medical University
Who can join
Adults 0 Months to 2, any sex, with Passive Transmission of Maternal and Infant Antibodies. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
At present, there is no relevant research focusing on children's acquisition of novel coronavirus antibodies through maternal passive transmission. Therefore, this study assessed the changes of maternal passive transmission of COVID-19 antibodies by monitoring the specific antibodies of COVID-19 in young children; This will lay a foundation for further exploring the risk of COVID-19 infection in children and formulating immune prevention strategies.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05851911
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Children's Hospital of Chongqing Medical University trials
Trials by the same sponsor.
- NCT06201013 — Vitamin D Treat-to-Target Strategy for Children With Overactive Bladder-Wet · NA · recruiting
- NCT07472829 — Research on Speech Development Trajectories and Predictive Models in Children With Autism Spectrum Disorder · not yet recruiting
- NCT05911893 — the Effect of High Caloric Oral Nutritional Supplements on Growth and Development of Malnourished Children · NA · recruiting
- NCT06404294 — The External Diaphragm Pacemaker Assisted Extubation in Premature Infants With Invasive Mechanical Ventilation · NA · recruiting
- NCT05768399 — The Role of Biomarkers in the Occurrence and Development of Asthma · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05851911 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Children's Hospital of Chongqing Medical University
- Last refreshed: 6 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05851911.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing